Author: R&D Team, CUIGUAI Flavoring
Published by: Guangdong Unique Flavor Co., Ltd.
Last Updated: Oct 12, 2026
WhatsApp & Telegram: +86 189 2926 7983
Email: info@cuiguai.com
In November 2021 the U.S. Food and Drug Administration moved against a small but highly visible corner of the vaping market: devices and e-liquids sold with vitamins or essential oils and marketed as wellness products. The agency issued warning letters to several companies, told them to stop making unproven health claims, and stated plainly that “no vaping products are approved by the FDA to prevent or treat any health conditions or diseases.” For an industry that had spent years competing on flavour and device design, the vitamin vape episode was a hard lesson in where marketing ends and regulation begins.
This article explains what “vitamin” vapes actually are, why regulators on both sides of the Atlantic pushed back so decisively, what the available science says about inhaling vitamins and essential oils, and — most importantly for suppliers and brand owners — how the backlash reshaped flavour strategy, label claims, and product development priorities. It is written for e-liquid brands, importers, and flavour buyers who need to understand both the compliance risk and the commercial opportunity that followed.
The short version is this: vitamins and essential oils are not the problem in themselves. The claims are. A flavour concentrate that tastes like mango is a flavour. The same concentrate sold as an immunity booster is, in the eyes of regulators, a drug. That distinction now shapes every stage of product development, from the brief given to a flavour house to the wording printed on a ten-millilitre bottle.
Brands that internalise the distinction can build defensible product lines. Brands that ignore it inherit warning letters, marketplace suspensions, customs detentions, and payment-processor problems — often all at once, and often without any prior chance to argue their case.
E-Liquid Flavour Laboratory Sample Vials and Batch Records | CUIGUAI
The products at the centre of the backlash were inhalable devices and e-liquids that added vitamin B12, vitamin C, melatonin, caffeine, or essential oils such as peppermint and eucalyptus to a base of propylene glycol and vegetable glycerine. They were sold as cartridges, disposables, and refillable pens, and they were priced well above conventional e-liquids on the strength of a wellness story rather than a nicotine strength.
The commercial logic was straightforward. As nicotine e-cigarettes faced tightening regulation and rising compliance costs, one segment of the market repositioned itself around benefits that had nothing to do with smoking cessation: focus, energy, immunity, relaxation, sleep quality, and hangover recovery. Product names borrowed the vocabulary of the supplement aisle, packaging mimicked vitamin bottles, and websites carried testimonials, condition-specific claims, and references to scientific-sounding concepts such as “inhalation science.”
The five firms that received FDA warning letters in November 2021 — Eagle Energy USA, NV Nutrition, VitaCig, Vitamin Vape, and VitaStik — illustrate the pattern precisely. Products were branded after the vitamin or the promised benefit, and the marketing copy went well beyond what a tobacco or supplement product is permitted to say. The letter to Vitamin Vape, Inc., dated 1 December 2021 and published under reference 617787, quotes website language presenting vitamin B12 as an “ideal candidate for vaporizing” and citing health information from the National Institutes of Health as support for an inhaled delivery claim.
That rhetorical move — borrowing a government health authority’s description of a nutrient’s role in the body and attaching it to an inhalation product — is the single most common compliance failure in this category. The quoted science was accurate about vitamin B12 as a nutrient. It said nothing about whether vitamin B12 survives a heating coil or reaches the bloodstream through the lungs.
A vitamin swallowed in a capsule and a vitamin inhaled as an aerosol are not regulated in the same way, and the difference is not a technicality. In the United States, a product intended for introduction into the body and marketed to affect the structure or function of the body, or to prevent or treat disease, meets the definition of a drug. Once that definition attaches, the product requires an approved new drug application under section 505(a) of the Federal Food, Drug, and Cosmetic Act — a pathway that no vaping product has ever completed.
In the European Union, the equivalent boundary sits between an e-cigarette regulated under the Tobacco Products Directive and a product presented as treating or preventing disease, which falls under medicinal product legislation. Either way, the trigger is not the ingredient. It is the claim. Reformulate the same liquid and rename it “mint flavour,” and the regulatory universe changes completely.
Regulatory Compliance File for Flavour Export Orders | CUIGUAI
On 9 November 2021 the FDA announced action to protect consumers from vaping products carrying unproven health claims. The agency described such products as illegally sold with unproven claims and potentially harmful when used. Warning letters followed to Eagle Energy USA, NV Nutrition, VitaCig, Vitamin Vape, and VitaStik, and the agency published its position in a consumer-facing notice titled “Beware of Vaping Products with Unproven Health Claims.”
Detailing the legal architecture of those letters matters, because the same structure recurs across the category. The FDA cited the introduction of an unapproved new drug under sections 301(d) and 505(a) of the FD&C Act, misbranding, and — where a product also met the definition of a tobacco product — the premarket authorisation requirement of section 910. A single wellness claim can therefore trigger several independent violations in one document.
Three overlapping theories were used against the category. The first treats the product as an unapproved new drug because it is marketed for a therapeutic or disease-prevention purpose without an approved application. The second treats a product presented as a dietary supplement as adulterated or misbranded because it is delivered by inhalation rather than ingestion, outside the intended routes for supplement use. The third is the one that most often catches flavour suppliers and brand owners by surprise.
Under the Deeming Rule, which became effective on 8 August 2016, the FDA extended its authority over e-cigarettes and e-liquids. Any product not on the market as of the 15 February 2007 grandfather date requires premarket authorisation — a PMTA with a marketing granted order — before it may legally be sold in the United States. That obligation applies whether or not a product contains nicotine, because the definition of a tobacco product turns on the product’s intended use and its components, not on nicotine content alone. As a result, an e-liquid sold as a wellness product can simultaneously be an unapproved drug and an unauthorised tobacco product. Brand owners who assume that “nicotine-free” equals “unregulated” are the ones most exposed, which is why our guide to common flavour-related citations in FDA warning letters is worth reading alongside this article.
Enforcement has not been confined to warning letters. FDA import alerts allow shipments to be detained without physical examination when a firm or product appears on the alert list, which means a container can be stopped at the port before a single unit reaches a retailer. State attorneys general have pursued consumer protection claims over health representations, and several U.S. states have enacted their own marketing restrictions on e-cigarettes and e-liquid packaging.
Private infrastructure enforces the same rules more quickly than any agency. Payment processors classify wellness vape transactions as high-risk and terminate merchant accounts over substantiation failures. Major marketplaces remove listings that make health claims, and shipping carriers have refused to move certain product categories. The cumulative effect is that one unsupported sentence on a product page can produce four simultaneous consequences: a regulatory letter, a delisted product, a frozen payment account, and a stopped container.
Regulatory Compliance File for Flavour Export Orders | CUIGUAI
Regulators did not need to prove that inhaled vitamins are harmful in order to act, because the violation was the claim rather than the chemistry. Even so, the scientific picture explains why the products were never likely to deliver what their marketing promised.
A vaping coil does not vaporise a liquid gently. Depending on power output, coil resistance, wick saturation, and puff duration, coil temperatures commonly reach well above the boiling point of the solvent base, and dry or partially saturated wicks push temperatures far higher. Heat-sensitive micronutrients sit in that environment for a fraction of a second, and many are sensitive to exactly those temperatures. Vitamin C, for example, is well known to degrade under heat and in the presence of oxygen, which is why food manufacturers protect it with cold chains, nitrogen flushing, and overage calculations rather than adding it to a hot process.
Vitamin B12 is comparatively more heat-stable in dry form, but stability in a stored tablet is not the same as stability in an aerosolised propylene glycol and glycerine matrix subjected to repeated heating cycles. Without product-specific analytical data, no one can state how much of the labelled dose survives the coil, and no such data was presented in the marketing that drew regulatory attention.
Even a molecule that survives the coil faces a second problem: where it lands. Particle size distribution determines whether an aerosol deposits in the upper airways, the conducting bronchi, or the deep alveolar region. Nutrition science establishes vitamin requirements and safe intake levels on the assumption of gastrointestinal absorption and hepatic processing, and the lungs are not a substitute route. Inhaled substances bypass first-pass metabolism and enter the systemic circulation directly, which changes both the speed and the pharmacokinetics of exposure.
That is exactly why regulators treat an inhaled therapeutic claim as a drug claim rather than a nutrition claim. Lipid-based carriers and oil-soluble ingredients are also associated with lipoid pneumonia risk when inhaled, a concern that applies equally to vitamin E acetate and to essential oils. Food-grade safety data does not automatically transfer to an inhalation route, and the flavour industry is explicit on this point: substances evaluated for ingestion are not thereby evaluated for inhalation.
Inside the European Union, nicotine-containing e-cigarettes and refill containers are governed by Article 20 of Directive 2014/40/EU. Some member states extend parts of that regime to nicotine-free products through national law, which is one reason a liquid can be legal in one capital and prohibited in another. Article 20 sets the familiar limits — a maximum nicotine concentration of 20 mg/ml, a maximum refill container volume of 10 ml, a maximum tank capacity of 2 ml — and requires manufacturers and importers to notify each product six months before it is placed on the market.
Two practical consequences follow for any wellness repositioning. First, adding a vitamin or essential oil changes the ingredient composition that must be declared, so a reformulated liquid is a new notification, not an amendment. Second, the moment the marketing copy describes treating, preventing, or alleviating a condition, the product leaves the TPD framework and is assessed as a medicinal product. Any brand operating in Europe should already be tracking the UFI codes required for European poison centre notification, because the same ingredient data underpins both obligations.
In the European Union, nutrition and health claims made on foods fall under Regulation (EC) No 1924/2006, under which only health claims authorised in the Union list may be used, and any claim must be substantiated by generally accepted scientific evidence. Words such as “supports normal immune function” or “contributes to normal energy metabolism” are not free-form marketing language in Europe; they are authorised claim formulations with defined conditions of use. Advertising a wellness vape with equivalent wording invites both food-law and consumer-protection scrutiny, and national authorities have taken action against vaping products framed as supporting immunity, concentration, or sleep.
Formulators at CUIGUAI develop flavour-first profiles that carry no therapeutic claims, keeping products inside tobacco and general product law.
The vitamin vape story did not reduce consumer appetite for differentiated flavour. It changed where that differentiation is allowed to live. After 2021 the credible path for brands is flavour complexity and sensory quality rather than functional promises, and that shift has quietly moved value back to the flavour house.
A flavour-first strategy replaces the promise of a biological outcome with a promise of taste experience. Instead of claiming that a liquid boosts immunity, a brand can claim that it reproduces the creamy mouthfeel of a fresh dairy drink, the acidity of blood orange, or the cooling curve of menthol with a controlled throat hit. These are sensory claims, they are verifiable in a tasting panel, and they do not require a drug application or an authorised health claim.
Reformulation work follows from that positioning. Where a wellness SKU once carried a vitamin additive, the replacement brief typically calls for a layered milk flavour system that delivers creaminess, sweetness, and body through the flavour compounds themselves, or for a concentrated orange flavour that provides genuine citrus brightness without any accompanying functional statement. The sensory outcome improves because the formulator is no longer hydrating a marketing concept.
Because the compliance risk sits in the claims rather than in the molecules, a flavour supplier becomes a valuable control point. A supplier that documents exactly what is in a concentrate, at what concentration, and with which classification protects the brand from accidental claim creep — the slow drift by which a technical descriptor becomes a consumer-facing benefit statement.
Ask whether every component is documented by chemical name and CAS number; whether the concentrate carries any CLP classification that would trigger additional labelling; whether the supplier will confirm in writing that no therapeutic, immune, or disease-related claim is supported by the formula; and whether the documentation package includes a stability summary and a retention sample policy. Suppliers who answer these questions confidently are usually the same suppliers whose batches pass customs without drama.
The vitamin vape backlash is best read not as a ban on innovation but as a clarification of the rules. Functional claims were never a durable differentiator in a category whose legal foundation rests on recreational flavour enjoyment, and the enforcement wave simply accelerated a correction that the science had already made inevitable. Inhaled vitamins cannot be dosed reliably, cannot be substantiated honestly, and cannot be marketed legally as therapeutic without a drug application that no vaping company has ever filed.
What remains is a large, competitive, and highly regulated flavour market in which sensory performance is the only claim that needs no disclaimer. That is a good outcome for manufacturers who invest in formulation, sensory science, and documentation — and a difficult one for anyone whose product idea depends on a promise the product cannot keep.
CUIGUAI develops flavour concentrates for e-liquid brands with the documentation that keeps marketers out of trouble: full ingredient disclosure, CAS-level specifications, certificates of analysis, retention samples, and formula briefs that are built around taste rather than therapeutic claims.
📞 Phone: +86 0769 8838 0789
🌐 Website: https://www.cuiguai.com
📧 Email: info@cuiguai.com
💬 WhatsApp & Telegram: +86 189 2926 7983
Tell us the profile you want to build — creamy, citrus, cooling, bakery, or tobacco — and our formulators will return a sample with the supporting documentation you need for your next market entry.
The business scope includes licensed projects: food additive production. General projects: sales of food additives; manufacturing of daily chemical products; sales of daily chemical products; technical services, technology development, technical consultation, technology exchange, technology transfer, and technology promotion; biological feed research and development; industrial enzyme preparation research and development; cosmetics wholesale; domestic trading agency; sales of sanitary products and disposable medical supplies; retail of kitchenware, sanitary ware and daily sundries; sales of daily necessities; food sales (only sales of pre-packaged food).
Copyright ©Guangdong Unique Flavor Co., Ltd.All Rights Reserved. Privacy Policy Return and Exchange Policy
